Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Determine the Pharmacokinetics of Mesalamine Following Administration of 30, 60, and 90 mg/kg/Day as 400 mg Delayed-release Tablets Given Every 12 Hours for 28 Days to Children/Adolescents With Active Ulcerative Colitis.

NCT00254618 is registered in ClinicalTrials.gov with Warner Chilcott as lead sponsor.

NCT NCT00254618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00254618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Determine the Pharmacokinetics of Mesalamine Following Administration of 30, 60, and 90 mg/kg/Day as 400 mg Delayed-release Tablets Given Every 12 Hours for 28 Days to Children/Adolescents With Active Ulcerative Colitis.
Lead sponsor
Warner Chilcott
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2005
Completion date
June 30, 2008
Enrollment
34 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis